Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
about
Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromesClopidogrel for the secondary prevention of strokeClinical use of new antithrombotic therapies for medical management of acute coronary syndromesRegular or "super-aspirins"? A review of thienopyridines or aspirin to prevent strokeTiclopidine versus oral anticoagulation for coronary stentingThe thienopyridinesSubacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpuraAntibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.Acute renal failure and thrombocytopenia after ticlopidine--not necessarily thrombotic thrombocytopenic purpura.Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review.Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome associated with clopidogrel: report of two new cases.Thrombotic thrombocytopenic purpura after percutaneous coronary intervention.Clopidogrel desensitization: case report and review of published protocols.Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).Thrombocytopenia following percutaneous coronary intervention.Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR).Low ADAMTS-13 in plavix induced thrombotic thrombocytopenic purpuraAcute pancreatitis-induced thrombotic thrombocytopenic purpura with recurrent acute pancreatitis.Antiplatelet medications and their indications in preventing and treating coronary thrombosis.Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Antiplatelet therapy in secondary stroke prevention--state of the artAntiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesTranslating from the rivers of Babylon to the coronary bloodstreamThe PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects.Antithrombotic medication for stroke prevention.Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.Antiplatelet therapy in acute coronary syndromes.Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel.Managing adverse effects and drug-drug interactions of antiplatelet agents.Novel antiplatelet therapies.Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.Metabolic differences of current thienopyridine antiplatelet agents.Pharmacotherapy for the reduction of stent thrombosis.Drug-induced thrombosis: an update.Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
P2860
Q24792611-8A58C287-1A16-4AE2-9552-F5EAC9720CDBQ28167896-9725C54F-1D24-4C6E-8AD8-CADA9359EAA2Q28176560-B005F2C3-8446-47A7-B669-0BC92B79BC77Q28177271-AFBA550A-543A-4AE4-B9D1-8830118766EFQ28183391-4D581F41-9FD1-41CE-B093-5D5D38633616Q28191104-69D57FBF-6902-4DDB-BA13-612ACA9DBB1AQ28193168-9CA8467B-D62B-4C14-B4F1-D252452832B9Q28213393-34BF7A2D-743C-47FB-A82F-65A8533416FBQ33332517-52854FD4-3AEE-4A0E-B6A8-7B5132374FF0Q33332873-46F66BF5-B02A-4836-98CE-750A52895811Q33335969-C629309C-31D9-4328-8C69-2E7FA0E53356Q33361713-16B70A7F-A4E3-4978-A665-74EA1B8A1D08Q33362149-90D88CA0-6045-4EFF-A073-4D811CD890FAQ33372278-A36DFC1B-E193-4DDB-802A-2AF523B47BCDQ33378440-31756154-C480-4DD2-8863-5155FA073DD1Q33383006-CC24788B-6AA5-42D2-A409-AB8476EED78EQ33387648-AC0A5FE7-BDD8-4876-8F14-B18BDD81F9BCQ33404125-1ED3A4A0-469B-475A-852A-EFFE20E906FCQ33406646-10328989-D942-47E3-9BDC-7B57DC8E33F8Q33411875-ED534F3F-F657-4944-B96B-0373663E6DA2Q33430220-50213052-D654-44AE-ACE0-DFDC33276C10Q34111901-35F22A13-DDC3-4E20-8626-3A39A62963F9Q34702595-AD915CFB-66A2-46A8-A636-8DCDE509EF3AQ34771381-ED7F08A4-9427-40CA-9150-CFCA81C45012Q35216412-9341CE9C-2260-49AB-B221-0E819BDFC94DQ35752619-430033C8-B69C-483A-9181-9E34D3512137Q36357988-B5FBB2CF-7945-45DF-96B4-D578CF682C1BQ36445381-090E6128-B313-4D48-87C3-1A63EAFFEF13Q37611046-BA4D626B-714E-4E57-93A7-FBA38B8F85FDQ37641606-0CAA3832-D7EA-4889-BC3C-8BDDE41369C3Q37798110-ADD0328D-489B-4A7D-AE13-35720B6A66FAQ37835616-170A58EB-205C-48D6-8465-1B0A44CEA26BQ37930967-AE6FF321-F009-4A2A-BE24-D95692D0955EQ37958763-DA7FC982-42A2-43B4-9C86-51D78A8245A4Q37982427-8F0499B7-4275-4F9E-84C1-C6CC2DB87576Q38053481-8B6D8C79-2E31-4374-AEE7-8DE6F7A2F835Q38071707-329BA8B7-19EF-48CE-9870-7FAB69374344Q38101963-B4FCB9F2-B799-4D39-9430-F4DD1F3A4620Q38103820-984B74E5-4F74-4082-8B1D-47C88323DF53Q38972064-24CCC50C-76D3-4551-A152-A7EF768E8E05
P2860
Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Incidence and clinical course ...... b/IIIa Inhibitor for Stenting.
@ast
Incidence and clinical course ...... b/IIIa Inhibitor for Stenting.
@en
Incidence and clinical course ...... b/IIIa Inhibitor for Stenting.
@nl
type
label
Incidence and clinical course ...... b/IIIa Inhibitor for Stenting.
@ast
Incidence and clinical course ...... b/IIIa Inhibitor for Stenting.
@en
Incidence and clinical course ...... b/IIIa Inhibitor for Stenting.
@nl
prefLabel
Incidence and clinical course ...... b/IIIa Inhibitor for Stenting.
@ast
Incidence and clinical course ...... b/IIIa Inhibitor for Stenting.
@en
Incidence and clinical course ...... b/IIIa Inhibitor for Stenting.
@nl
P2093
P356
P1476
Incidence and clinical course ...... b/IIIa Inhibitor for Stenting.
@en
P2093
P304
P356
10.1001/JAMA.281.9.806
P407
P50
P577
1999-03-01T00:00:00Z